- In recent days, President Donald Trump publicly promoted cannabidiol (CBD) as a prescription drug alternative and backed its potential to transform senior healthcare, sparking optimism about possible federal regulatory changes in the U.S. that could impact cannabis businesses.
- Aurora Cannabis, which generates most of its revenue from medical cannabis, is especially exposed to benefits from regulatory shifts such as marijuana rescheduling that may ease financial and operational constraints for sector participants.
- We’ll now examine how potential changes in U.S. cannabis policy, highlighted by recent presidential endorsements of CBD, may influence Aurora’s investment narrative.
Uncover the next big thing with financially sound penny stocks that balance risk and reward.
Aurora Cannabis Investment Narrative Recap
To own shares in Aurora Cannabis, an investor would need to believe that global acceptance and regulatory normalization of…
